A recent study published in The Journal of Urology this month suggests that stereotactic body radiotherapy (SBRT) may be a safe and effective therapeutic option that could control the growth of localised, small numbers of metastases (oligometastatic) in people with advanced renal cell carcinoma (RCC).
Fifty-eight RCC patients, who had undergone surgery and had a maximum of 3 metastases, were treated with SBRT. Patients were followed for up to 5 years after SBRT.
Local control rate was 90.2% at both 12 and 18 months, and progression-free survival (PFS) rates were 46.2% and 35%, respectively. Median overall survival (OS) was 28.4 months, and 1-, 2-, and 5-year survival rates were 100%, 100%, and 83%, respectively.
The authors concluded that “future prospective studies are necessary to evaluate [SBRT’s] impact on survival and quality of life. Moreover, a new prospective on the radiobiology of RCC should be considered to better understand the role of SBRT and, particularly, its possible interaction with medical therapies.”